Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort

Nephrology Dialysis Transplantation

Volumn 26, Issue 4, 2011, Pages 1258-1265

  Isakova, Tamara ^a   Anderson, Cheryl A M ^b   Leonard, Mary B ^c   Xie, Dawei ^c   Gutiérrez, Orlando M ^a   Rosen, Leigh K ^c   Theurer, Jacquie ^d   Bellovich, Keith ^e   Steigerwalt, Susan P ^e   Tang, Ignatius ^f   Anderson, Amanda Hyre ^c   Townsend, Raymond R ^g   He, Jiang ^h   Feldman, Harold I ^c,g   Wolf, Myles ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

^e St John's Health System   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h TULANE UNIVERSITY   (United States)

Author keywords

calciuria; chronic kidney disease; diuretics; parathyroid hormone

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; CALCITRIOL; CALCIUM; DIURETIC AGENT; LOOP DIURETIC AGENT; PARATHYROID HORMONE; PHOSPHATE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ADULT; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; DRUG DOSE COMPARISON; FEMALE; GLOMERULUS FILTRATION RATE; HISPANIC; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; VITAMIN SUPPLEMENTATION;

ADULT; AGED; CALCIUM; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIURETICS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROGNOSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 79953850264     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr026     Document Type: Article

References (44)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047 (Pubitemid 350074801)
2. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010; 362: 56-65
3. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309
4. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215 (Pubitemid 41716454)
5. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38 (Pubitemid 44967731)
6. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218 (Pubitemid 39031360)
7. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008; 74: 721-731
8. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Secondary hyperpara-thyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008; 73: 1296-1302 (Pubitemid 351693159)
9. Hagstrom E, Hellman P, Larsson TE et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009; 119: 2765-2771
10. Gutierrez OM, Mannstadt M, Isakova Tet al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
11. Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 640-648
12. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
13. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with loop diuretics. J Intern Med 2006; 259: 117-124
14. Lim LS, Fink HA, Kuskowski MA et al. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med 2008; 168: 735-740 (Pubitemid 351563957)
15. Carbone LD, Johnson KC, Bush AJ et al. Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative. Arch Intern Med 2009; 169: 132-140
16. Lim LS, Fink HA, Blackwell Tet al. Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women. J Am Geriatr Soc 2009; 57: 855-862
17. LaCroix AZ, Wienpahl J, White LR et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990; 322: 286-290 (Pubitemid 20046330)
18. Schoofs MW, van der Klift M, Hofman A et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139: 476-482
19. Ott SM, LaCroix AZ, Scholes D et al. Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int 2008; 19: 1315-1322
20. Feldman HI, Appel LJ, Chertow GM et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods. J Am Soc Nephrol 2003; 14: S148-S153 (Pubitemid 36750511)
21. Subar AF, Thompson FE, Kipnis V et al. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol 2001; 154: 1089-1099 (Pubitemid 33140629)
22. Worcester EM, Gillen DL, Evan AP et al. Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis. Am J Physiol Renal Physiol 2007; 292: F66-F75 (Pubitemid 46105244)
23. Breslau NA, McGuire JL, Zerwekh JE et al. The role of dietary sodium on renal excretion and intestinal absorption of calcium and on vitamin D metabolism. J Clin Endocrinol Metab 1982; 55: 369-373 (Pubitemid 13238744)
24. D'Agostino RBJr., D'Agostino RBSr. Estimating treatment effects using observational data. JAMA 2007; 297: 314-316 (Pubitemid 46143312)
25. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456 (Pubitemid 36910023)
26. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013 (Pubitemid 47530570)
27. Bricker NS, Slatopolsky E, Reiss E et al. Calcium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med 1969; 123: 543-553
28. Llach F, Massry SG. On the mechanism of secondary hyperparathyr-oidism in moderate renal insufficiency. J Clin Endocrinol Metab 1985; 61: 601-606 (Pubitemid 16248077)
29. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980
30. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008 (Pubitemid 350224109)
31. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218
32. Coburn JW, Koppel MH, Brickman AS et al. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 1973; 3: 264-272
33. Craver L, Marco MP, Martinez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 15-achievement of K/ DOQI target ranges. Nephrol Dial Transplant 2007; 22: 1171-1176 (Pubitemid 46523434)
34. Taylor EN, Curhan GC. Demographic, dietary, and urinary factors and 24-h urinary calcium excretion. Clin J Am Soc Nephrol 2009; 4: 1980-1987
35. Coe FL, Canterbury JM, Firpo JJ et al. Evidence for secondary hyper-parathyroidism in idiopathic hypercalciuria. J Clin Invest 1973; 52: 134-142
36. Stein MS, Scherer SC, Walton SL et al. Risk factors for secondary hyperparathyroidism in a nursing home population. Clin Endocrinol (Oxf) 1996; 44: 375-383 (Pubitemid 26142876)
37. Reichel H, Deibert B, Geberth S et al. Frusemide therapy and intact parathyroid hormone plasma concentrations in chronic renal insufficiency. Nephrol Dial Transplant 1992; 7: 8-15
38. Rejnmark L, Vestergaard P, Pedersen AR et al. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmeno-pausal osteopenic women. Eur J Clin Invest 2003; 33: 41-50 (Pubitemid 36051290)
39. Rejnmark L, Vestergaard P, Heickendorff L et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postme-nopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 2006; 21: 163-170 (Pubitemid 43023238)
40. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009; 361: 2153-2164
41. Segura J, Ruilope LM. Should diuretics always be included as initial antihypertensive managementin early-stage CKD? Curr Opin Nephrol Hypertens 2009; 18: 392-396
42. Hoenderop JG, van Leeuwen JP, van der Eerden BC et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003; 112: 1906-1914 (Pubitemid 38063714)
43. Bibbins-Domingo K, Chertow GM, Coxson PG et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010; 362: 590-599
44. Appel LJ, Anderson CA. Compelling evidence for public health action to reduce salt intake. N Engl J Med 2010; 362: 650-652